ID   PAX6_HUMAN              Reviewed;         422 AA.
AC   P26367; Q6N006; Q99413;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   18-JUN-2025, entry version 260.
DE   RecName: Full=Paired box protein Pax-6;
DE   AltName: Full=Aniridia type II protein;
DE   AltName: Full=Oculorhombin;
GN   Name=PAX6; Synonyms=AN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal eye;
RX   PubMed=1684738; DOI=10.1016/0092-8674(91)90284-6;
RA   Ton C.C.T., Hirvonen H., Miwa H., Weil M.M., Monaghan P., Jordan T.,
RA   van Heyningen V., Hastie N.D., Meijers-Heijboer H., Drechsler M.,
RA   Royer-Pokora B., Collins F.S., Swaroop A., Strong L.C., Saunders G.F.;
RT   "Positional cloning and characterization of a paired box- and homeobox-
RT   containing gene from the aniridia region.";
RL   Cell 67:1059-1074(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1345175; DOI=10.1038/ng1192-232;
RA   Glaser T., Walton D.S., Maas R.L.;
RT   "Genomic structure, evolutionary conservation and aniridia mutations in the
RT   human PAX6 gene.";
RL   Nat. Genet. 2:232-239(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Liu J., Zhang B., Zhou Y., Peng X., Yuan J., Qiang B.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5A).
RC   TISSUE=Cerebellum;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ALTERNATIVE SPLICING, DNA-BINDING, AND TISSUE SPECIFICITY.
RX   PubMed=7958875; DOI=10.1101/gad.8.17.2022;
RA   Epstein J.A., Glaser T., Cai J., Jepeal L., Walton D.S., Maas R.L.;
RT   "Two independent and interactive DNA-binding subdomains of the Pax6 paired
RT   domain are regulated by alternative splicing.";
RL   Genes Dev. 8:2022-2034(1994).
RN   [8]
RP   INVOLVEMENT IN KERH.
RX   PubMed=7668281;
RA   Mirzayans F., Pearce W.G., MacDonald I.M., Walter M.A.;
RT   "Mutation of the PAX6 gene in patients with autosomal dominant keratitis.";
RL   Am. J. Hum. Genet. 57:539-548(1995).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=19414065; DOI=10.1016/j.ijdevneu.2009.04.004;
RA   Larsen K.B., Lutterodt M., Rath M.F., Moeller M.;
RT   "Expression of the homeobox genes PAX6, OTX2, and OTX1 in the early human
RT   fetal retina.";
RL   Int. J. Dev. Neurosci. 27:485-492(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   INVOLVEMENT IN AN2.
RX   PubMed=24290376; DOI=10.1016/j.ajhg.2013.10.028;
RA   Bhatia S., Bengani H., Fish M., Brown A., Divizia M.T., de Marco R.,
RA   Damante G., Grainger R., van Heyningen V., Kleinjan D.A.;
RT   "Disruption of autoregulatory feedback by a mutation in a remote,
RT   ultraconserved PAX6 enhancer causes aniridia.";
RL   Am. J. Hum. Genet. 93:1126-1134(2013).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 4-136.
RX   PubMed=10346815; DOI=10.1101/gad.13.10.1263;
RA   Xu H.E., Rould M.A., Xu W., Epstein J.A., Maas R.L., Pabo C.O.;
RT   "Crystal structure of the human Pax-6 paired domain-DNA complex reveals
RT   specific roles for the linker region and carboxyl-terminal subdomain in DNA
RT   binding.";
RL   Genes Dev. 13:1263-1275(1999).
RN   [14]
RP   REVIEW ON VARIANTS.
RX   PubMed=9482572;
RX   DOI=10.1002/(sici)1098-1004(1998)11:2<93::aid-humu1>3.0.co;2-m;
RA   Prosser J., van Heyningen V.;
RT   "PAX6 mutations reviewed.";
RL   Hum. Mutat. 11:93-108(1998).
RN   [15]
RP   STRUCTURE BY NMR OF 211-277.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the homeobox domain of the human paired box protein
RT   PAX-6.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [16]
RP   VARIANT AN1 TRP-208.
RX   PubMed=8364574; DOI=10.1093/hmg/2.7.915;
RA   Hanson I.M., Seawright A., Hardman K., Hodgson S., Zaletayev D., Fekete G.,
RA   van Heyningen V.;
RT   "PAX6 mutations in aniridia.";
RL   Hum. Mol. Genet. 2:915-920(1993).
RN   [17]
RP   VARIANT ASGD5 GLY-26.
RX   PubMed=8162071; DOI=10.1038/ng0294-168;
RA   Hanson I.M., Fletcher J.M., Jordan T., Brown A., Taylor D., Adams R.J.,
RA   Punnet H.H., van Heyningen V.;
RT   "Mutations at the PAX6 locus are found in heterogeneous anterior segment
RT   malformations including Peters' anomaly.";
RL   Nat. Genet. 6:168-173(1994).
RN   [18]
RP   VARIANTS FVH1 CYS-125 AND CYS-128.
RX   PubMed=8640214; DOI=10.1038/ng0696-141;
RA   Azuma N., Nishina S., Yanagisawa H., Okuyama T., Yamada M.;
RT   "PAX6 missense mutation in isolated foveal hypoplasia.";
RL   Nat. Genet. 13:141-142(1996).
RN   [19]
RP   VARIANT AN1 ARG-87, AND VARIANT GLY-26.
RX   PubMed=9147640; DOI=10.1093/hmg/6.3.381;
RA   Tang H.K., Chao L.-Y., Saunders G.F.;
RT   "Functional analysis of paired box missense mutations in the PAX6 gene.";
RL   Hum. Mol. Genet. 6:381-386(1997).
RN   [20]
RP   VARIANT AN1 22-PRO--ARG-26 DEL.
RX   PubMed=9281415; DOI=10.1006/mcpr.1997.0117;
RA   Axton R., Hanson I.M., Love J., Seawright A., Prosser J., van Heyningen V.;
RT   "Combined SSCP/heteroduplex analysis in the screening for PAX6 mutations.";
RL   Mol. Cell. Probes 11:287-292(1997).
RN   [21]
RP   VARIANT AN1 TRP-18.
RX   PubMed=9792406;
RX   DOI=10.1002/(sici)1098-1004(1998)12:5<304::aid-humu3>3.0.co;2-d;
RA   Wolf M.T.F., Lorenz B., Winterpacht A., Drechsler M., Schumacher V.,
RA   Royer-Pokora B., Blankenagel A., Zabel B., Wildhardt G.;
RT   "Ten novel mutations found in Aniridia.";
RL   Hum. Mutat. 12:304-313(1998).
RN   [22]
RP   VARIANT EYE MALFORMATIONS ARG-422.
RX   PubMed=9538891;
RA   Azuma N., Yamada M.;
RT   "Missense mutation at the C-terminus of the PAX6 gene in ocular anterior
RT   segment anomalies.";
RL   Invest. Ophthalmol. Vis. Sci. 39:828-830(1998).
RN   [23]
RP   VARIANTS AN1 SER-17; VAL-29; GLN-44 AND HIS-178.
RX   PubMed=9856761;
RA   Azuma N., Hotta Y., Tanaka H., Yamada M.;
RT   "Missense mutations in the PAX6 gene in aniridia.";
RL   Invest. Ophthalmol. Vis. Sci. 39:2524-2528(1998).
RN   [24]
RP   VARIANT ASGD5 ASP-53.
RX   PubMed=10441571; DOI=10.1086/302529;
RA   Azuma N., Yamaguchi Y., Handa H., Hayakawa M., Kanai A., Yamada M.;
RT   "Missense mutation in the alternative splice region of the PAX6 gene in eye
RT   anomalies.";
RL   Am. J. Hum. Genet. 65:656-663(1999).
RN   [25]
RP   ALTERNATIVE SPLICING, AND VARIANTS AN1 SER-42; LEU-53; PRO-63; GLU-79 AND
RP   GLN-208.
RX   PubMed=10234503; DOI=10.1038/sj.ejhg.5200308;
RA   Groenskov K., Rosenberg T., Sand A., Broendum-Nielsen K.;
RT   "Mutational analysis of PAX6: 16 novel mutations including 5 missense
RT   mutations with a mild aniridia phenotype.";
RL   Eur. J. Hum. Genet. 7:274-286(1999).
RN   [26]
RP   VARIANTS AN1 PRO-33; PRO-43 AND ASP-126, AND VARIANT FVH1 VAL-64.
RX   PubMed=9931324; DOI=10.1093/hmg/8.2.165;
RA   Hanson I.M., Churchill A., Love J., Axton R., Moore T., Clarke M.,
RA   Meire F., van Heyningen V.;
RT   "Missense mutations in the most ancient residues of the PAX6 paired domain
RT   underlie a spectrum of human congenital eye malformations.";
RL   Hum. Mol. Genet. 8:165-172(1999).
RN   [27]
RP   VARIANTS AN1 SER-29; ARG-119 AND ALA-353.
RA   Wildhardt G.;
RL   Unpublished observations (APR-1999).
RN   [28]
RP   VARIANT AN1 37-ALA--PRO-39 DEL.
RA   Saunders G.F.;
RL   Unpublished observations (AUG-1999).
RN   [29]
RP   VARIANT NYSTAGMUS ARG-118.
RX   PubMed=10955655; DOI=10.1007/s004170000124;
RA   Sonoda S., Isashiki Y., Tabata Y., Kimura K., Kakiuchi T., Ohba N.;
RT   "A novel PAX6 gene mutation (P118R) in a family with congenital nystagmus
RT   associated with a variant form of aniridia.";
RL   Graefes Arch. Clin. Exp. Ophthalmol. 238:552-558(2000).
RN   [30]
RP   VARIANT AN1 37-ARG--PRO-39 DEL, AND VARIANT ASP-387.
RX   PubMed=10737978;
RX   DOI=10.1002/(sici)1098-1004(200004)15:4<332::aid-humu5>3.0.co;2-1;
RA   Chao L.-Y., Huff V., Strong L.C., Saunders G.F.;
RT   "Mutation in the PAX6 gene in twenty patients with aniridia.";
RL   Hum. Mutat. 15:332-339(2000).
RN   [31]
RP   VARIANT AN1 ARG-119.
RX   PubMed=11553050; DOI=10.1034/j.1399-0004.2001.600210.x;
RA   Malandrini A., Mari F., Palmeri S., Gambelli S., Berti G., Bruttini M.,
RA   Bardelli A.M., Williamson K., van Heyningen V., Renieri A.;
RT   "PAX6 mutation in a family with aniridia, congenital ptosis, and mental
RT   retardation.";
RL   Clin. Genet. 60:151-154(2001).
RN   [32]
RP   VARIANTS AN1 GLN-375 AND ARG-422.
RX   PubMed=11309364; DOI=10.1093/hmg/10.9.911;
RA   Singh S., Chao L.-Y., Mishra R., Davies J., Saunders G.F.;
RT   "Missense mutation at the C-terminus of PAX6 negatively modulates
RT   homeodomain function.";
RL   Hum. Mol. Genet. 10:911-918(2001).
RN   [33]
RP   VARIANT AN1 THR-242.
RX   PubMed=11826019; DOI=10.1136/jmg.39.1.16;
RA   Morrison D., FitzPatrick D., Hanson I., Williamson K., van Heyningen V.,
RA   Fleck B., Jones I., Chalmers J., Campbell H.;
RT   "National study of microphthalmia, anophthalmia, and coloboma (MAC) in
RT   Scotland: investigation of genetic aetiology.";
RL   J. Med. Genet. 39:16-22(2002).
RN   [34]
RP   INVOLVEMENT IN OPTIC-NERVE MALFORMATIONS, VARIANT MORNING GLORY DISK
RP   ANOMALY SER-68, VARIANT COLON SER-258, VARIANT MCOPCB12 SER-258, VARIANT
RP   ASGD5 PRO-363, AND VARIANTS BONH ILE-292; ARG-378; VAL-381 AND ALA-391.
RX   PubMed=12721955; DOI=10.1086/375555;
RA   Azuma N., Yamaguchi Y., Handa H., Tadokoro K., Asaka A., Kawase E.,
RA   Yamada M.;
RT   "Mutations of the PAX6 gene detected in patients with a variety of optic-
RT   nerve malformations.";
RL   Am. J. Hum. Genet. 72:1565-1570(2003).
RN   [35]
RP   VARIANTS AN1 PRO-19 AND 22-PRO--ARG-26 DEL.
RX   PubMed=12634864; DOI=10.1038/sj.ejhg.5200940;
RA   Vincent M.-C., Pujo A.-L., Olivier D., Calvas P.;
RT   "Screening for PAX6 gene mutations is consistent with haploinsufficiency as
RT   the main mechanism leading to various ocular defects.";
RL   Eur. J. Hum. Genet. 11:163-169(2003).
RN   [36]
RP   VARIANTS AN1 ARG-46; ARG-52; THR-56; ASP-73 AND LYS-87, VARIANT THR-321,
RP   CHARACTERIZATION OF VARIANTS AN1 ARG-46; ARG-52; LEU-53; THR-56 AND ASP-73,
RP   AND CHARACTERIZATION OF VARIANT THR-321.
RX   PubMed=12552561; DOI=10.1002/humu.10163;
RA   Chao L.-Y., Mishra R., Strong L.C., Saunders G.F.;
RT   "Missense mutations in the DNA-binding region and termination codon in
RT   PAX6.";
RL   Hum. Mutat. 21:138-145(2003).
RN   [37]
RP   CHARACTERIZATION OF VARIANT AN1 THR-242.
RX   PubMed=16493447; DOI=10.1038/sj.ejhg.5201579;
RA   D'Elia A.V., Puppin C., Pellizzari L., Pianta A., Bregant E., Lonigro R.,
RA   Tell G., Fogolari F., van Heyningen V., Damante G.;
RT   "Molecular analysis of a human PAX6 homeobox mutant.";
RL   Eur. J. Hum. Genet. 14:744-751(2006).
RN   [38]
RP   INVOLVEMENT IN AN1.
RX   PubMed=17595013; DOI=10.1002/ajmg.a.31808;
RA   Graziano C., D'Elia A.V., Mazzanti L., Moscano F., Guidelli Guidi S.,
RA   Scarano E., Turchetti D., Franzoni E., Romeo G., Damante G., Seri M.;
RT   "A de novo nonsense mutation of PAX6 gene in a patient with aniridia,
RT   ataxia, and mental retardation.";
RL   Am. J. Med. Genet. A 143:1802-1805(2007).
RN   [39]
RP   VARIANT AN1 ARG-395.
RX   PubMed=21850189;
RA   Zhang X., Wang P., Li S., Xiao X., Guo X., Zhang Q.;
RT   "Mutation spectrum of PAX6 in Chinese patients with aniridia.";
RL   Mol. Vis. 17:2139-2147(2011).
RN   [40]
RP   VARIANT AN1 PRO-19.
RX   PubMed=24033328; DOI=10.1111/cge.12275;
RA   Chassaing N., Causse A., Vigouroux A., Delahaye A., Alessandri J.L.,
RA   Boespflug-Tanguy O., Boute-Benejean O., Dollfus H., Duban-Bedu B.,
RA   Gilbert-Dussardier B., Giuliano F., Gonzales M., Holder-Espinasse M.,
RA   Isidor B., Jacquemont M.L., Lacombe D., Martin-Coignard D.,
RA   Mathieu-Dramard M., Odent S., Picone O., Pinson L., Quelin C., Sigaudy S.,
RA   Toutain A., Thauvin-Robinet C., Kaplan J., Calvas P.;
RT   "Molecular findings and clinical data in a cohort of 150 patients with
RT   anophthalmia/microphthalmia.";
RL   Clin. Genet. 86:326-334(2014).
RN   [41]
RP   VARIANT FVH1 GLN-38.
RX   PubMed=29914532; DOI=10.1186/s13023-018-0828-0;
RA   Li J., Leng Y., Han S., Yan L., Lu C., Luo Y., Zhang X., Cao L.;
RT   "Clinical and genetic characteristics of Chinese patients with familial or
RT   sporadic pediatric cataract.";
RL   Orphanet J. Rare Dis. 13:94-94(2018).
CC   -!- FUNCTION: Transcription factor with important functions in the
CC       development of the eye, nose, central nervous system and pancreas.
CC       Required for the differentiation of pancreatic islet alpha cells (By
CC       similarity). Competes with PAX4 in binding to a common element in the
CC       glucagon, insulin and somatostatin promoters. Regulates specification
CC       of the ventral neuron subtypes by establishing the correct progenitor
CC       domains (By similarity). Acts as a transcriptional repressor of NFATC1-
CC       mediated gene expression (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P63015}.
CC   -!- SUBUNIT: Interacts with MAF and MAFB (By similarity). Interacts with
CC       TRIM11; this interaction leads to ubiquitination and proteasomal
CC       degradation, as well as inhibition of transactivation, possibly in part
CC       by preventing PAX6 binding to consensus DNA sequences (By similarity).
CC       Interacts with TLE6/GRG6 (By similarity).
CC       {ECO:0000250|UniProtKB:P63015}.
CC   -!- INTERACTION:
CC       P26367; Q8WYK0: ACOT12; NbExp=3; IntAct=EBI-747278, EBI-11954993;
CC       P26367; Q9NX04: AIRIM; NbExp=3; IntAct=EBI-747278, EBI-8643161;
CC       P26367; Q9BXS5: AP1M1; NbExp=3; IntAct=EBI-747278, EBI-541426;
CC       P26367; O95376: ARIH2; NbExp=3; IntAct=EBI-747278, EBI-711158;
CC       P26367; Q8N8Y2: ATP6V0D2; NbExp=3; IntAct=EBI-747278, EBI-3923949;
CC       P26367; Q8NEY4-2: ATP6V1C2; NbExp=3; IntAct=EBI-747278, EBI-10270867;
CC       P26367; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-747278, EBI-11524452;
CC       P26367; Q5TBC7: BCL2L15; NbExp=3; IntAct=EBI-747278, EBI-10247136;
CC       P26367; Q53TS8: C2CD6; NbExp=3; IntAct=EBI-747278, EBI-739879;
CC       P26367; Q8IW40: CCDC103; NbExp=3; IntAct=EBI-747278, EBI-10261970;
CC       P26367; Q16204: CCDC6; NbExp=3; IntAct=EBI-747278, EBI-1045350;
CC       P26367; Q9Y258: CCL26; NbExp=3; IntAct=EBI-747278, EBI-7783416;
CC       P26367; Q00526: CDK3; NbExp=3; IntAct=EBI-747278, EBI-1245761;
CC       P26367; Q9UFW8: CGGBP1; NbExp=3; IntAct=EBI-747278, EBI-723153;
CC       P26367; Q13111: CHAF1A; NbExp=3; IntAct=EBI-747278, EBI-1020839;
CC       P26367; Q96Q77: CIB3; NbExp=3; IntAct=EBI-747278, EBI-10292696;
CC       P26367; Q9BW66: CINP; NbExp=3; IntAct=EBI-747278, EBI-739784;
CC       P26367; P61024: CKS1B; NbExp=3; IntAct=EBI-747278, EBI-456371;
CC       P26367; P68400: CSNK2A1; NbExp=5; IntAct=EBI-747278, EBI-347804;
CC       P26367; Q9UI47-2: CTNNA3; NbExp=3; IntAct=EBI-747278, EBI-11962928;
CC       P26367; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-747278, EBI-12024320;
CC       P26367; P49366: DHPS; NbExp=3; IntAct=EBI-747278, EBI-741925;
CC       P26367; Q96JC9: EAF1; NbExp=3; IntAct=EBI-747278, EBI-769261;
CC       P26367; Q5JVL4: EFHC1; NbExp=3; IntAct=EBI-747278, EBI-743105;
CC       P26367; Q8N9N8: EIF1AD; NbExp=3; IntAct=EBI-747278, EBI-750700;
CC       P26367; P62508-3: ESRRG; NbExp=3; IntAct=EBI-747278, EBI-12001340;
CC       P26367; Q9Y247: FAM50B; NbExp=3; IntAct=EBI-747278, EBI-742802;
CC       P26367; Q8NHY3: GAS2L2; NbExp=3; IntAct=EBI-747278, EBI-7960826;
CC       P26367; O75603: GCM2; NbExp=3; IntAct=EBI-747278, EBI-10188645;
CC       P26367; O14893: GEMIN2; NbExp=3; IntAct=EBI-747278, EBI-443648;
CC       P26367; O95872: GPANK1; NbExp=3; IntAct=EBI-747278, EBI-751540;
CC       P26367; Q6ISB3: GRHL2; NbExp=3; IntAct=EBI-747278, EBI-10219092;
CC       P26367; O14964: HGS; NbExp=3; IntAct=EBI-747278, EBI-740220;
CC       P26367; Q6NT76: HMBOX1; NbExp=3; IntAct=EBI-747278, EBI-2549423;
CC       P26367; O15347: HMGB3; NbExp=3; IntAct=EBI-747278, EBI-2214136;
CC       P26367; P07910: HNRNPC; NbExp=3; IntAct=EBI-747278, EBI-357966;
CC       P26367; Q9NSC5: HOMER3; NbExp=6; IntAct=EBI-747278, EBI-748420;
CC       P26367; P49639: HOXA1; NbExp=3; IntAct=EBI-747278, EBI-740785;
CC       P26367; P31273: HOXC8; NbExp=3; IntAct=EBI-747278, EBI-1752118;
CC       P26367; P31274: HOXC9; NbExp=3; IntAct=EBI-747278, EBI-1779423;
CC       P26367; Q63ZY3: KANK2; NbExp=3; IntAct=EBI-747278, EBI-2556193;
CC       P26367; Q96MP8-2: KCTD7; NbExp=3; IntAct=EBI-747278, EBI-11954971;
CC       P26367; Q9BYQ3: KRTAP9-3; NbExp=3; IntAct=EBI-747278, EBI-1043191;
CC       P26367; Q9BYQ0: KRTAP9-8; NbExp=3; IntAct=EBI-747278, EBI-11958364;
CC       P26367; Q6P4E2: LARP4; NbExp=3; IntAct=EBI-747278, EBI-12079790;
CC       P26367; Q9C0E8-2: LNPK; NbExp=3; IntAct=EBI-747278, EBI-11024283;
CC       P26367; Q17RB8: LONRF1; NbExp=3; IntAct=EBI-747278, EBI-2341787;
CC       P26367; Q9BS40: LXN; NbExp=3; IntAct=EBI-747278, EBI-1044504;
CC       P26367; Q96S90: LYSMD1; NbExp=3; IntAct=EBI-747278, EBI-10293291;
CC       P26367; Q15691: MAPRE1; NbExp=3; IntAct=EBI-747278, EBI-1004115;
CC       P26367; P55081: MFAP1; NbExp=3; IntAct=EBI-747278, EBI-1048159;
CC       P26367; Q8TD10: MIPOL1; NbExp=3; IntAct=EBI-747278, EBI-2548751;
CC       P26367; Q8IVT2: MISP; NbExp=3; IntAct=EBI-747278, EBI-2555085;
CC       P26367; Q6PF18: MORN3; NbExp=3; IntAct=EBI-747278, EBI-9675802;
CC       P26367; Q96EL3: MRPL53; NbExp=3; IntAct=EBI-747278, EBI-2513715;
CC       P26367; Q9UBB6: NCDN; NbExp=3; IntAct=EBI-747278, EBI-1053490;
CC       P26367; Q8NI38: NFKBID; NbExp=3; IntAct=EBI-747278, EBI-10271199;
CC       P26367; Q13952-2: NFYC; NbExp=3; IntAct=EBI-747278, EBI-11956831;
CC       P26367; Q96IV0: NGLY1; NbExp=3; IntAct=EBI-747278, EBI-6165879;
CC       P26367; Q08493-2: PDE4C; NbExp=3; IntAct=EBI-747278, EBI-12169289;
CC       P26367; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-747278, EBI-79165;
CC       P26367; Q13526: PIN1; NbExp=3; IntAct=EBI-747278, EBI-714158;
CC       P26367; Q9BUI4: POLR3C; NbExp=3; IntAct=EBI-747278, EBI-5452779;
CC       P26367; Q9BT43: POLR3GL; NbExp=3; IntAct=EBI-747278, EBI-2855862;
CC       P26367; Q8WUA2: PPIL4; NbExp=3; IntAct=EBI-747278, EBI-2513119;
CC       P26367; P54619: PRKAG1; NbExp=3; IntAct=EBI-747278, EBI-1181439;
CC       P26367; Q9UIG4: PSORS1C2; NbExp=3; IntAct=EBI-747278, EBI-11974061;
CC       P26367; Q2TAL8: QRICH1; NbExp=3; IntAct=EBI-747278, EBI-2798044;
CC       P26367; Q9UBE0: SAE1; NbExp=3; IntAct=EBI-747278, EBI-743154;
CC       P26367; Q9UDX3: SEC14L4; NbExp=3; IntAct=EBI-747278, EBI-10320311;
CC       P26367; Q01105-2: SET; NbExp=3; IntAct=EBI-747278, EBI-7481343;
CC       P26367; O43699-3: SIGLEC6; NbExp=3; IntAct=EBI-747278, EBI-12161783;
CC       P26367; A0AV02: SLC12A8; NbExp=3; IntAct=EBI-747278, EBI-11737524;
CC       P26367; Q5MJ68: SPDYC; NbExp=3; IntAct=EBI-747278, EBI-12162209;
CC       P26367; Q9NZD8: SPG21; NbExp=3; IntAct=EBI-747278, EBI-742688;
CC       P26367; Q05519-2: SRSF11; NbExp=3; IntAct=EBI-747278, EBI-11975029;
CC       P26367; Q99469: STAC; NbExp=3; IntAct=EBI-747278, EBI-2652799;
CC       P26367; Q9NUJ3: TCP11L1; NbExp=3; IntAct=EBI-747278, EBI-2555179;
CC       P26367; Q96FV9: THOC1; NbExp=3; IntAct=EBI-747278, EBI-1765605;
CC       P26367; Q9UKI8: TLK1; NbExp=3; IntAct=EBI-747278, EBI-740492;
CC       P26367; Q86UE8: TLK2; NbExp=3; IntAct=EBI-747278, EBI-1047967;
CC       P26367; O75865-2: TRAPPC6A; NbExp=3; IntAct=EBI-747278, EBI-8451480;
CC       P26367; Q15642-2: TRIP10; NbExp=3; IntAct=EBI-747278, EBI-6550597;
CC       P26367; Q969M7: UBE2F; NbExp=3; IntAct=EBI-747278, EBI-1056876;
CC       P26367; P61086: UBE2K; NbExp=3; IntAct=EBI-747278, EBI-473850;
CC       P26367; Q14CS0: UBXN2B; NbExp=3; IntAct=EBI-747278, EBI-1993619;
CC       P26367; O94888: UBXN7; NbExp=3; IntAct=EBI-747278, EBI-1993627;
CC       P26367; Q8N6Y0: USHBP1; NbExp=3; IntAct=EBI-747278, EBI-739895;
CC       P26367; Q3SXR9: VCX2; NbExp=3; IntAct=EBI-747278, EBI-11983741;
CC       P26367; Q9Y3C0: WASHC3; NbExp=3; IntAct=EBI-747278, EBI-712969;
CC       P26367; O96006: ZBED1; NbExp=3; IntAct=EBI-747278, EBI-740037;
CC       P26367; Q15973: ZNF124; NbExp=3; IntAct=EBI-747278, EBI-2555767;
CC       P26367; Q86VK4-3: ZNF410; NbExp=3; IntAct=EBI-747278, EBI-11741890;
CC       P26367; A0A384ME25; NbExp=3; IntAct=EBI-747278, EBI-10211777;
CC       P26367; P63168: Dynll1; Xeno; NbExp=3; IntAct=EBI-747278, EBI-349121;
CC       P26367-1; P63166: Sumo1; Xeno; NbExp=2; IntAct=EBI-15892945, EBI-80152;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:P63015}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus
CC       {ECO:0000250|UniProtKB:P63016}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 5a]: Nucleus
CC       {ECO:0000250|UniProtKB:P63016}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P26367-1; Sequence=Displayed;
CC       Name=5a; Synonyms=Pax6-5a;
CC         IsoId=P26367-2; Sequence=VSP_002366;
CC       Name=3; Synonyms=Pax6-5A,6*;
CC         IsoId=P26367-3; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed in lymphoblasts.
CC       {ECO:0000269|PubMed:7958875}.
CC   -!- TISSUE SPECIFICITY: [Isoform 5a]: Weakly expressed in lymphoblasts.
CC       {ECO:0000269|PubMed:7958875}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the developing eye and brain.
CC       Expression in the retina peaks at fetal days 51-60. At 6-week old, in
CC       the retina, is predominantly detected in the neural layer (at protein
CC       level). At 8- and 10-week old, in the retina, the expression is
CC       strongest in the inner and middle layer of the neural part (at protein
CC       level). {ECO:0000269|PubMed:19414065}.
CC   -!- PTM: Ubiquitinated by TRIM11, leading to ubiquitination and proteasomal
CC       degradation. {ECO:0000250}.
CC   -!- DISEASE: Aniridia 1 (AN1) [MIM:106210]: A congenital, bilateral,
CC       panocular disorder characterized by complete absence of the iris or
CC       extreme iris hypoplasia. Aniridia is not just an isolated defect in
CC       iris development but it is associated with macular and optic nerve
CC       hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is
CC       generally low but is unrelated to the degree of iris hypoplasia.
CC       Glaucoma is a secondary problem causing additional visual loss over
CC       time. {ECO:0000269|PubMed:10234503, ECO:0000269|PubMed:10737978,
CC       ECO:0000269|PubMed:11309364, ECO:0000269|PubMed:11553050,
CC       ECO:0000269|PubMed:11826019, ECO:0000269|PubMed:12552561,
CC       ECO:0000269|PubMed:12634864, ECO:0000269|PubMed:16493447,
CC       ECO:0000269|PubMed:17595013, ECO:0000269|PubMed:21850189,
CC       ECO:0000269|PubMed:24033328, ECO:0000269|PubMed:8364574,
CC       ECO:0000269|PubMed:9147640, ECO:0000269|PubMed:9281415,
CC       ECO:0000269|PubMed:9792406, ECO:0000269|PubMed:9856761,
CC       ECO:0000269|PubMed:9931324, ECO:0000269|Ref.27, ECO:0000269|Ref.28}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Anterior segment dysgenesis 5 (ASGD5) [MIM:604229]: A form of
CC       anterior segment dysgenesis, a group of defects affecting anterior
CC       structures of the eye including cornea, iris, lens, trabecular
CC       meshwork, and Schlemm canal. Anterior segment dysgeneses result from
CC       abnormal migration or differentiation of the neural crest derived
CC       mesenchymal cells that give rise to components of the anterior chamber
CC       during eye development. Different anterior segment anomalies may exist
CC       alone or in combination, including iris hypoplasia, enlarged or reduced
CC       corneal diameter, corneal vascularization and opacity, posterior
CC       embryotoxon, corectopia, polycoria, abnormal iridocorneal angle,
CC       ectopia lentis, and anterior synechiae between the iris and posterior
CC       corneal surface. Clinical conditions falling within the phenotypic
CC       spectrum of anterior segment dysgeneses include aniridia, Axenfeld
CC       anomaly, Reiger anomaly/syndrome, Peters anomaly, and
CC       iridogoniodysgenesis. {ECO:0000269|PubMed:10441571,
CC       ECO:0000269|PubMed:12721955, ECO:0000269|PubMed:8162071}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Foveal hypoplasia 1 (FVH1) [MIM:136520]: An isolated form of
CC       foveal hypoplasia, a developmental defect of the eye defined as the
CC       lack of foveal depression with continuity of all neurosensory retinal
CC       layers in the presumed foveal area. Clinical features include absence
CC       of foveal pit on optical coherence tomography, absence of foveal
CC       hyperpigmentation, absence of foveal avascularity, absence of foveal
CC       and macular reflexes, decreased visual acuity, and nystagmus. Anterior
CC       segment anomalies and cataract are observed in some FVH1 patients.
CC       {ECO:0000269|PubMed:29914532, ECO:0000269|PubMed:8640214,
CC       ECO:0000269|PubMed:9931324}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Keratitis hereditary (KERH) [MIM:148190]: An ocular disorder
CC       characterized by corneal opacification, recurrent stromal keratitis and
CC       vascularization. {ECO:0000269|PubMed:7668281}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- DISEASE: Microphthalmia/coloboma 12 (MCOPCB12) [MIM:120200]: A form of
CC       colobomatous microphthalmia, a disorder of eye formation, ranging from
CC       small size of a single eye to complete bilateral absence of ocular
CC       tissues. Ocular abnormalities like coloboma, opacities of the cornea
CC       and lens, scaring of the retina and choroid, and other abnormalities
CC       may also be present. Ocular colobomas are a set of malformations
CC       resulting from abnormal morphogenesis of the optic cup and stalk, and
CC       the fusion of the fetal fissure (optic fissure). MCOPCB12 is an
CC       autosomal dominant form characterized by inter- and intrafamilial
CC       variability. Some patients also exhibit neurodevelopmental anomalies.
CC       {ECO:0000269|PubMed:12721955}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Coloboma of optic nerve (COLON) [MIM:120430]: An ocular defect
CC       that is due to malclosure of the fetal intraocular fissure affecting
CC       the optic nerve head. In some affected individuals, it appears as
CC       enlargement of the physiologic cup with severely affected eyes showing
CC       huge cavities at the site of the disk. {ECO:0000269|PubMed:12721955}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Bilateral optic nerve hypoplasia (BONH) [MIM:165550]: A
CC       congenital anomaly in which the optic disk appears abnormally small. It
CC       may be an isolated finding or part of a spectrum of anatomic and
CC       functional abnormalities that includes partial or complete agenesis of
CC       the septum pellucidum, other midline brain defects, cerebral anomalies,
CC       pituitary dysfunction, and structural abnormalities of the pituitary.
CC       {ECO:0000269|PubMed:12721955}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Aniridia 2 (AN2) [MIM:617141]: A form of aniridia, a
CC       congenital, bilateral, panocular disorder characterized by complete
CC       absence of the iris or extreme iris hypoplasia. Aniridia is not just an
CC       isolated defect in iris development but it is associated with macular
CC       and optic nerve hypoplasia, cataract, corneal changes, nystagmus.
CC       Visual acuity is generally low but is unrelated to the degree of iris
CC       hypoplasia. Glaucoma is a secondary problem causing additional visual
CC       loss over time. {ECO:0000269|PubMed:24290376}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis. A
CC       mutation in a PAX6 long-range cis-regulatory element, known as SIMO,
CC       affects PAX6 expression in the developing eye and has pathological
CC       consequences. The mutation is located in ELP4 intron 9, 150 kb
CC       downstream of PAX6. {ECO:0000269|PubMed:24290376}.
CC   -!- SIMILARITY: Belongs to the paired homeobox family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Human PAX6 allelic variant database web site;
CC       URL="http://pax6.hgu.mrc.ac.uk/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/211/PAX6";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M77844; AAA59962.1; -; mRNA.
DR   EMBL; M93650; AAA36416.1; -; mRNA.
DR   EMBL; AY047583; AAK95849.1; -; mRNA.
DR   EMBL; BX640762; CAE45868.1; -; mRNA.
DR   EMBL; Z83307; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z95332; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC011953; AAH11953.1; -; mRNA.
DR   CCDS; CCDS31451.1; -. [P26367-1]
DR   CCDS; CCDS31452.1; -. [P26367-2]
DR   PIR; A56674; A56674.
DR   RefSeq; NP_000271.1; NM_000280.6. [P26367-1]
DR   RefSeq; NP_001121084.1; NM_001127612.3. [P26367-1]
DR   RefSeq; NP_001245391.1; NM_001258462.3. [P26367-2]
DR   RefSeq; NP_001245392.1; NM_001258463.2. [P26367-2]
DR   RefSeq; NP_001245393.1; NM_001258464.2. [P26367-1]
DR   RefSeq; NP_001245394.1; NM_001258465.3. [P26367-1]
DR   RefSeq; NP_001297087.1; NM_001310158.2. [P26367-2]
DR   RefSeq; NP_001297088.1; NM_001310159.1.
DR   RefSeq; NP_001297090.1; NM_001310161.1.
DR   RefSeq; NP_001355816.1; NM_001368887.2. [P26367-1]
DR   RefSeq; NP_001355817.1; NM_001368888.2. [P26367-1]
DR   RefSeq; NP_001355818.1; NM_001368889.2. [P26367-1]
DR   RefSeq; NP_001355819.1; NM_001368890.2. [P26367-1]
DR   RefSeq; NP_001355820.1; NM_001368891.2. [P26367-1]
DR   RefSeq; NP_001355821.1; NM_001368892.2. [P26367-2]
DR   RefSeq; NP_001355822.1; NM_001368893.2. [P26367-2]
DR   RefSeq; NP_001355823.1; NM_001368894.2. [P26367-2]
DR   RefSeq; NP_001595.2; NM_001604.5. [P26367-2]
DR   PDB; 2CUE; NMR; -; A=211-277.
DR   PDB; 6PAX; X-ray; 2.50 A; A=4-136.
DR   PDBsum; 2CUE; -.
DR   PDBsum; 6PAX; -.
DR   AlphaFoldDB; P26367; -.
DR   BMRB; P26367; -.
DR   SMR; P26367; -.
DR   BioGRID; 111114; 349.
DR   CORUM; P26367; -.
DR   DIP; DIP-37436N; -.
DR   FunCoup; P26367; 3249.
DR   IntAct; P26367; 328.
DR   MINT; P26367; -.
DR   STRING; 9606.ENSP00000492024; -.
DR   GlyGen; P26367; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P26367; -.
DR   PhosphoSitePlus; P26367; -.
DR   BioMuta; PAX6; -.
DR   DMDM; 6174889; -.
DR   jPOST; P26367; -.
DR   MassIVE; P26367; -.
DR   PaxDb; 9606-ENSP00000404100; -.
DR   PeptideAtlas; P26367; -.
DR   ProteomicsDB; 54323; -. [P26367-1]
DR   ProteomicsDB; 54324; -. [P26367-2]
DR   Pumba; P26367; -.
DR   Antibodypedia; 12821; 996 antibodies from 48 providers.
DR   DNASU; 5080; -.
DR   Ensembl; ENST00000241001.13; ENSP00000241001.8; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000379107.7; ENSP00000368401.2; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000379109.7; ENSP00000368403.2; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000379129.7; ENSP00000368424.2; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000379132.8; ENSP00000368427.2; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000419022.6; ENSP00000404100.1; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000606377.7; ENSP00000480026.1; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000638914.3; ENSP00000492315.2; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000639409.1; ENSP00000492476.1; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000639916.1; ENSP00000490963.1; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000640287.1; ENSP00000492822.1; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000640368.2; ENSP00000492024.1; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000640610.1; ENSP00000491295.1; ENSG00000007372.25. [P26367-1]
DR   Ensembl; ENST00000640975.1; ENSP00000491872.1; ENSG00000007372.25. [P26367-2]
DR   Ensembl; ENST00000643871.1; ENSP00000495109.1; ENSG00000007372.25. [P26367-1]
DR   GeneID; 5080; -.
DR   KEGG; hsa:5080; -.
DR   MANE-Select; ENST00000640368.2; ENSP00000492024.1; NM_001368894.2; NP_001355823.1. [P26367-2]
DR   UCSC; uc001mtg.6; human. [P26367-1]
DR   AGR; HGNC:8620; -.
DR   CTD; 5080; -.
DR   DisGeNET; 5080; -.
DR   GeneCards; PAX6; -.
DR   GeneReviews; PAX6; -.
DR   HGNC; HGNC:8620; PAX6.
DR   HPA; ENSG00000007372; Group enriched (brain, retina).
DR   MalaCards; PAX6; -.
DR   MIM; 106210; phenotype.
DR   MIM; 120200; phenotype.
DR   MIM; 120430; phenotype.
DR   MIM; 136520; phenotype.
DR   MIM; 148190; phenotype.
DR   MIM; 165550; phenotype.
DR   MIM; 604229; phenotype.
DR   MIM; 607108; gene.
DR   MIM; 617141; phenotype.
DR   OpenTargets; ENSG00000007372; -.
DR   Orphanet; 1065; Aniridia-cerebellar ataxia-intellectual disability syndrome.
DR   Orphanet; 2334; Autosomal dominant keratitis.
DR   Orphanet; 98942; Coloboma of choroid and retina.
DR   Orphanet; 98943; Coloboma of eye lens.
DR   Orphanet; 98946; Coloboma of eyelid.
DR   Orphanet; 98944; Coloboma of iris.
DR   Orphanet; 98945; Coloboma of macula.
DR   Orphanet; 98947; Coloboma of optic disc.
DR   Orphanet; 2253; Foveal hypoplasia-presenile cataract syndrome.
DR   Orphanet; 250923; Isolated aniridia.
DR   Orphanet; 35737; Morning glory disc anomaly.
DR   Orphanet; 708; Peters anomaly.
DR   Orphanet; 893; WAGR syndrome.
DR   VEuPathDB; HostDB:ENSG00000007372; -.
DR   eggNOG; KOG0849; Eukaryota.
DR   GeneTree; ENSGT00940000155391; -.
DR   HOGENOM; CLU_019281_1_0_1; -.
DR   InParanoid; P26367; -.
DR   OMA; YSHAHST; -.
DR   OrthoDB; 3225452at2759; -.
DR   PAN-GO; P26367; 4 GO annotations based on evolutionary models.
DR   PhylomeDB; P26367; -.
DR   PathwayCommons; P26367; -.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1).
DR   Reactome; R-HSA-400511; Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP).
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-9823739; Formation of the anterior neural plate.
DR   SignaLink; P26367; -.
DR   SIGNOR; P26367; -.
DR   BioGRID-ORCS; 5080; 15 hits in 1165 CRISPR screens.
DR   ChiTaRS; PAX6; human.
DR   EvolutionaryTrace; P26367; -.
DR   GeneWiki; PAX6; -.
DR   GenomeRNAi; 5080; -.
DR   Pharos; P26367; Tbio.
DR   PRO; PR:P26367; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P26367; protein.
DR   Bgee; ENSG00000007372; Expressed in palpebral conjunctiva and 148 other cell types or tissues.
DR   ExpressionAtlas; P26367; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0070410; F:co-SMAD binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:BHF-UCL.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IEA:Ensembl.
DR   GO; GO:0035035; F:histone acetyltransferase binding; ISS:BHF-UCL.
DR   GO; GO:0071837; F:HMG box domain binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; ISS:BHF-UCL.
DR   GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0001221; F:transcription coregulator binding; ISS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0048708; P:astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0001568; P:blood vessel development; IMP:DFLAT.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0001709; P:cell fate determination; IEA:Ensembl.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0021796; P:cerebral cortex regionalization; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0061303; P:cornea development in camera-type eye; IMP:DFLAT.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0000132; P:establishment of mitotic spindle orientation; IEA:Ensembl.
DR   GO; GO:0001654; P:eye development; TAS:ProtInc.
DR   GO; GO:0042462; P:eye photoreceptor cell development; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IBA:GO_Central.
DR   GO; GO:0021798; P:forebrain dorsal/ventral pattern formation; IEA:Ensembl.
DR   GO; GO:0021905; P:forebrain-midbrain boundary formation; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:DFLAT.
DR   GO; GO:0021986; P:habenula development; IEA:Ensembl.
DR   GO; GO:0061072; P:iris morphogenesis; IMP:DFLAT.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0032808; P:lacrimal gland development; IEA:Ensembl.
DR   GO; GO:0002088; P:lens development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IMP:BHF-UCL.
DR   GO; GO:0007405; P:neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0048663; P:neuron fate commitment; NAS:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0021778; P:oligodendrocyte cell fate specification; IEA:Ensembl.
DR   GO; GO:0003322; P:pancreatic A cell development; IMP:BHF-UCL.
DR   GO; GO:0021983; P:pituitary gland development; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0030858; P:positive regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; IDA:BHF-UCL.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0033365; P:protein localization to organelle; IEA:Ensembl.
DR   GO; GO:0009786; P:regulation of asymmetric cell division; IEA:Ensembl.
DR   GO; GO:0030334; P:regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0048505; P:regulation of timing of cell differentiation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0009611; P:response to wounding; IEP:UniProtKB.
DR   GO; GO:0060041; P:retina development in camera-type eye; IBA:GO_Central.
DR   GO; GO:0007435; P:salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0007423; P:sensory organ development; IBA:GO_Central.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0003309; P:type B pancreatic cell differentiation; IBA:GO_Central.
DR   GO; GO:0021517; P:ventral spinal cord development; ISS:UniProtKB.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   CDD; cd00086; homeodomain; 1.
DR   CDD; cd00131; PAX; 1.
DR   FunFam; 1.10.10.10:FF:000003; Paired box protein Pax-6; 1.
DR   FunFam; 1.10.10.10:FF:000069; Paired box protein Pax-6; 1.
DR   FunFam; 1.10.10.60:FF:000028; Paired box protein Pax-6; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 2.
DR   IDEAL; IID00197; -.
DR   InterPro; IPR001356; HD.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR009057; Homeodomain-like_sf.
DR   InterPro; IPR043182; PAIRED_DNA-bd_dom.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR043565; PAX_fam.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   PANTHER; PTHR45636:SF48; PAIRED BOX PROTEIN PAX-6; 1.
DR   PANTHER; PTHR45636; PAIRED BOX PROTEIN PAX-6-RELATED-RELATED; 1.
DR   Pfam; PF00046; Homeodomain; 1.
DR   Pfam; PF00292; PAX; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00389; HOX; 1.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; Homeodomain-like; 2.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
DR   neXtProt; NX_P26367; -.
DR   PharmGKB; PA32960; -.
DR   TreeFam; TF320146; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Developmental protein; Differentiation;
KW   Disease variant; DNA-binding; Homeobox; Nucleus; Paired box;
KW   Peters anomaly; Proteomics identification; Reference proteome; Repressor;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..422
FT                   /note="Paired box protein Pax-6"
FT                   /id="PRO_0000050185"
FT   DNA_BIND        4..130
FT                   /note="Paired"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   DNA_BIND        210..269
FT                   /note="Homeobox"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00108"
FT   REGION          7..63
FT                   /note="PAI subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          82..130
FT                   /note="RED subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00381"
FT   REGION          162..201
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          269..311
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          345..422
FT                   /note="Required for suppression of NFATC1-mediated
FT                   transcription"
FT                   /evidence="ECO:0000250|UniProtKB:P63015"
FT   COMPBIAS        281..294
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VAR_SEQ         47
FT                   /note="Q -> QTHADAKVQVLDNQN (in isoform 5a)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_002366"
FT   VARIANT         17
FT                   /note="N -> S (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9856761"
FT                   /id="VAR_003808"
FT   VARIANT         18
FT                   /note="G -> W (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9792406"
FT                   /id="VAR_003809"
FT   VARIANT         19
FT                   /note="R -> P (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:12634864,
FT                   ECO:0000269|PubMed:24033328"
FT                   /id="VAR_047860"
FT   VARIANT         22..26
FT                   /note="Missing (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:12634864,
FT                   ECO:0000269|PubMed:9281415"
FT                   /id="VAR_008693"
FT   VARIANT         26
FT                   /note="R -> G (in ASGD5; dbSNP:rs121907913)"
FT                   /evidence="ECO:0000269|PubMed:8162071,
FT                   ECO:0000269|PubMed:9147640"
FT                   /id="VAR_003810"
FT   VARIANT         29
FT                   /note="I -> S (in AN1)"
FT                   /evidence="ECO:0000269|Ref.27"
FT                   /id="VAR_008694"
FT   VARIANT         29
FT                   /note="I -> V (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9856761"
FT                   /id="VAR_003811"
FT   VARIANT         33
FT                   /note="A -> P (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9931324"
FT                   /id="VAR_008695"
FT   VARIANT         37..39
FT                   /note="Missing (in AN1)"
FT                   /evidence="ECO:0000269|Ref.28"
FT                   /id="VAR_008696"
FT   VARIANT         38
FT                   /note="R -> Q (in FVH1; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:29914532"
FT                   /id="VAR_084825"
FT   VARIANT         42
FT                   /note="I -> S (in AN1; mild)"
FT                   /evidence="ECO:0000269|PubMed:10234503"
FT                   /id="VAR_008697"
FT   VARIANT         43
FT                   /note="S -> P (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9931324"
FT                   /id="VAR_008698"
FT   VARIANT         44
FT                   /note="R -> Q (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9856761"
FT                   /id="VAR_003812"
FT   VARIANT         46
FT                   /note="L -> R (in AN1; shows almost no binding efficiency;
FT                   transcriptional activation ability is about 50% lower than
FT                   that of the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047861"
FT   VARIANT         52
FT                   /note="C -> R (in AN1; shows almost no binding efficiency;
FT                   transcriptional activation ability is about 50% lower than
FT                   that of the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047862"
FT   VARIANT         53
FT                   /note="V -> D (in ASGD5; also found in patients with
FT                   congenital cataract and foveal hypoplasia)"
FT                   /evidence="ECO:0000269|PubMed:10441571"
FT                   /id="VAR_008700"
FT   VARIANT         53
FT                   /note="V -> L (in AN1; mild; shows 50% lower DNA-binding
FT                   and transactivation ability than the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:10234503,
FT                   ECO:0000269|PubMed:12552561"
FT                   /id="VAR_008699"
FT   VARIANT         56
FT                   /note="I -> T (in AN1; shows only one-quarter to one-third
FT                   the binding ability of the normal wild-type protein;
FT                   exhibits normal transactivation)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047863"
FT   VARIANT         63
FT                   /note="T -> P (in AN1; mild)"
FT                   /evidence="ECO:0000269|PubMed:10234503"
FT                   /id="VAR_008701"
FT   VARIANT         64
FT                   /note="G -> V (in foveal hypoplasia; associated with
FT                   presenile cataract syndrome; dbSNP:rs121907920)"
FT                   /evidence="ECO:0000269|PubMed:9931324"
FT                   /id="VAR_008702"
FT   VARIANT         68
FT                   /note="P -> S (in morning glory disk anomaly; significant
FT                   impairment of transcriptional activation ability;
FT                   dbSNP:rs121907923)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017540"
FT   VARIANT         73
FT                   /note="G -> D (in AN1; shows almost no binding efficiency;
FT                   transcriptional activation ability is about 80% of that of
FT                   the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047864"
FT   VARIANT         79
FT                   /note="A -> E (in AN1; mild)"
FT                   /evidence="ECO:0000269|PubMed:10234503"
FT                   /id="VAR_008703"
FT   VARIANT         87
FT                   /note="I -> K (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047865"
FT   VARIANT         87
FT                   /note="I -> R (in AN1; loss of activity)"
FT                   /evidence="ECO:0000269|PubMed:9147640"
FT                   /id="VAR_003813"
FT   VARIANT         118
FT                   /note="P -> R (in a family with nystagmus associated with a
FT                   variant form of aniridia)"
FT                   /evidence="ECO:0000269|PubMed:10955655"
FT                   /id="VAR_015065"
FT   VARIANT         119
FT                   /note="S -> R (in AN1; dbSNP:rs121907928)"
FT                   /evidence="ECO:0000269|PubMed:11553050, ECO:0000269|Ref.27"
FT                   /id="VAR_008704"
FT   VARIANT         125
FT                   /note="R -> C (in FVH1; isolated)"
FT                   /evidence="ECO:0000269|PubMed:8640214"
FT                   /id="VAR_017541"
FT   VARIANT         126
FT                   /note="V -> D (in AN1; atypical form; dbSNP:rs121907919)"
FT                   /evidence="ECO:0000269|PubMed:9931324"
FT                   /id="VAR_008705"
FT   VARIANT         128
FT                   /note="R -> C (in FVH1; isolated; dbSNP:rs121907918)"
FT                   /evidence="ECO:0000269|PubMed:8640214"
FT                   /id="VAR_003814"
FT   VARIANT         178
FT                   /note="Q -> H (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:9856761"
FT                   /id="VAR_003815"
FT   VARIANT         208
FT                   /note="R -> Q (in AN1; mild; dbSNP:rs749244084)"
FT                   /evidence="ECO:0000269|PubMed:10234503"
FT                   /id="VAR_008706"
FT   VARIANT         208
FT                   /note="R -> W (in AN1; dbSNP:rs757259413)"
FT                   /evidence="ECO:0000269|PubMed:8364574"
FT                   /id="VAR_003816"
FT   VARIANT         242
FT                   /note="R -> T (in AN1; the mutant homeodomain binds DNA as
FT                   well as the wild-type homeodomain; the mutant does not
FT                   modify the DNA-binding properties of the paired domain; the
FT                   steady-state levels of the full-length mutant protein are
FT                   higher than those of the wild-type one; a responsive
FT                   promoter is activated to a higher extent by the mutant
FT                   protein than by the wild-type protein; the presence of the
FT                   mutation reduces sensitivity to trypsin digestion;
FT                   dbSNP:rs121907927)"
FT                   /evidence="ECO:0000269|PubMed:11826019,
FT                   ECO:0000269|PubMed:16493447"
FT                   /id="VAR_047866"
FT   VARIANT         258
FT                   /note="F -> S (in MCOPCB12 and COLON; significant
FT                   impairment of transcriptional activation ability;
FT                   dbSNP:rs121907925)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017542"
FT   VARIANT         292
FT                   /note="S -> I (in BONH; significant impairment of ability
FT                   to activate transcription)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017543"
FT   VARIANT         321
FT                   /note="A -> T (shows about two-fold higher binding
FT                   efficiency than the normal wild-type protein;
FT                   transcriptional activation ability is about 89% of that of
FT                   the wild-type protein)"
FT                   /evidence="ECO:0000269|PubMed:12552561"
FT                   /id="VAR_047867"
FT   VARIANT         353
FT                   /note="S -> A (in AN1; dbSNP:rs373661718)"
FT                   /evidence="ECO:0000269|Ref.27"
FT                   /id="VAR_008707"
FT   VARIANT         363
FT                   /note="S -> P (in ASGD5)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017544"
FT   VARIANT         375
FT                   /note="P -> Q (in AN1; reduced DNA binding ability;
FT                   dbSNP:rs200015827)"
FT                   /evidence="ECO:0000269|PubMed:11309364"
FT                   /id="VAR_015066"
FT   VARIANT         378
FT                   /note="Q -> R (in optic nerve aplasia)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017545"
FT   VARIANT         381
FT                   /note="M -> V (in BONH)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017546"
FT   VARIANT         387
FT                   /note="G -> D (in dbSNP:rs1392343463)"
FT                   /evidence="ECO:0000269|PubMed:10737978"
FT                   /id="VAR_047868"
FT   VARIANT         391
FT                   /note="T -> A (in BONH; dbSNP:rs121907926)"
FT                   /evidence="ECO:0000269|PubMed:12721955"
FT                   /id="VAR_017547"
FT   VARIANT         395
FT                   /note="G -> R (in AN1)"
FT                   /evidence="ECO:0000269|PubMed:21850189"
FT                   /id="VAR_067698"
FT   VARIANT         422
FT                   /note="Q -> R (in AN1 and ocular anterior segment
FT                   anomalies; loss of DNA binding ability; dbSNP:rs780356070)"
FT                   /evidence="ECO:0000269|PubMed:11309364,
FT                   ECO:0000269|PubMed:9538891"
FT                   /id="VAR_008708"
FT   CONFLICT        317
FT                   /note="R -> L (in Ref. 1; AAA59962)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        369
FT                   /note="Y -> C (in Ref. 4; CAE45868)"
FT                   /evidence="ECO:0000305"
FT   STRAND          6..8
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   STRAND          14..16
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           23..34
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           39..46
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           50..63
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   STRAND          77..79
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           81..93
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           99..108
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   TURN            114..116
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           120..133
FT                   /evidence="ECO:0007829|PDB:6PAX"
FT   HELIX           219..229
FT                   /evidence="ECO:0007829|PDB:2CUE"
FT   HELIX           237..246
FT                   /evidence="ECO:0007829|PDB:2CUE"
FT   HELIX           251..275
FT                   /evidence="ECO:0007829|PDB:2CUE"
SQ   SEQUENCE   422 AA;  46683 MW;  C33CDD2C1B13C397 CRC64;
     MQNSHSGVNQ LGGVFVNGRP LPDSTRQKIV ELAHSGARPC DISRILQVSN GCVSKILGRY
     YETGSIRPRA IGGSKPRVAT PEVVSKIAQY KRECPSIFAW EIRDRLLSEG VCTNDNIPSV
     SSINRVLRNL ASEKQQMGAD GMYDKLRMLN GQTGSWGTRP GWYPGTSVPG QPTQDGCQQQ
     EGGGENTNSI SSNGEDSDEA QMRLQLKRKL QRNRTSFTQE QIEALEKEFE RTHYPDVFAR
     ERLAAKIDLP EARIQVWFSN RRAKWRREEK LRNQRRQASN TPSHIPISSS FSTSVYQPIP
     QPTTPVSSFT SGSMLGRTDT ALTNTYSALP PMPSFTMANN LPMQPPVPSQ TSSYSCMLPT
     SPSVNGRSYD TYTPPHMQTH MNSQPMGTSG TTSTGLISPG VSVPVQVPGS EPDMSQYWPR
     LQ
//
